In a development that could bring a measure of stability to state-legal medical cannabis programs, the federal budget proposal put forward by President Donald Trump includes language designed to protect those programs from federal interference. Under the proposed spending plan, federal agencies would be barred from using appropriated funds to disrupt or prosecute medical marijuana activity that complies with state law—a rider that has been a key part of federal appropriations for years and one that supporters say helps safeguard patient access and provider participation.
While this budget language doesn’t change cannabis’s status under federal law, it does reinforce a long-standing congressional practice of limiting federal action against state medical cannabis systems. That practice traces back to appropriations riders first enacted in the 2010s to protect state programs from Department of Justice enforcement, and continuing it in 2026 would signal ongoing federal reluctance to upend state medical markets.
The inclusion of medical cannabis protections in the budget comes amid broader shifts in federal cannabis policy. The administration has also moved to advance rescheduling of cannabis under the Controlled Substances Act, a process that was set in motion by a 2025 executive order directing cannabis to be reclassified to a lower schedule—a change that could eventually reduce regulatory burdens if fully implemented.
At the same time, other parts of the cannabis landscape continue to evolve, including proposed Medicare rules that could expand coverage for hemp-derived products and state-level legalization efforts gaining traction in places like North Carolina and Hawaii.
For patients, providers, and businesses operating in the medical cannabis space, the budget proposal’s protections don’t represent a permanent legal guarantee—but they do offer a degree of predictability and reassurance in an industry long shaped by uncertainty at the federal level.
Dabbin-Dad Newsroom
